Product Information

Migalastat is a piperidine compound.

CAS No.	108147-54-2
Product Name	Migalastat

Biological Targets

GLA

Associated Conditions

Fabry disease

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Journal of medical genetics • Vol. 54, Issue 4 • 2017

PMID: 27834756 PMC: PMC5502308 DOI: 10.1136/jmedgenet-2016-104178

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

PloS one • Vol. 10, Issue 8 • 2015

PMID: 26252393 PMC: PMC4529213 DOI: 10.1371/journal.pone.0134341

A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Human mutation • Vol. 32, Issue 8 • 2011

PMID: 21598360 PMC: PMC3170878 DOI: 10.1002/humu.21530

Enzyme replacement therapy for Fabry disease: some answers but more questions.

Therapeutics and clinical risk management • Vol. 7 • 2011

PMID: 21445281 PMC: PMC3061846 DOI: 10.2147/TCRM.S11987

Migalastat

CAS No.	108147-54-2
MDL No.	N/A
MF	C₆H₁₃NO₄
MW	163.17
InChI Key	LXBIFEVIBLOUGU-DPYQTVNSSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Migalastat is a piperidine compound.

CAS No.	108147-54-2
Product Name	Migalastat

Biological Targets

GLA

Associated Conditions

Fabry disease

* The information provided here is compiled from public sources and is for reference only.

Migalastat

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Migalastat

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Migalastat

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Enzyme replacement therapy for Fabry disease: some answers but more questions.

Similar Products

Migalastat Hydrochloride

1-Deoxynojirimycin

1-Deoxynojirimycin Hydrochloride

Migalastat

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Enzyme replacement therapy for Fabry disease: some answers but more questions.

Similar Products

Migalastat Hydrochloride

1-Deoxynojirimycin

1-Deoxynojirimycin Hydrochloride

Documentation